Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia

Masahiro Takahara, Yasuhiro Miyake, Hirokazu Miyatake, Atsushi Imagawa, Morihito Nakatsu, Masaharu Ando, Mamoru Hirohata, Kazuhide Yamamoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective Platelet counts before starting the treatment affect the discontinuation and dose reduction of peginterferon in chronic hepatitis C. Thrombocytopenia leads to failure to achieve sustained virological response. This study was undertaken to evaluate the efficacy of partial splenic embolization (PSE) prior to starting peginterferon therapy combined with ribavirin in chronic hepatitis C patients showing thrombocytopenia.Patients and Methods We compared the clinical features of 11 patients receiving PSE (PSE group) prior to starting the combined therapy with those of 13 patients not receiving PSE (non-PSE group). All of the patients showed platelet counts 12×10 4/mm 3 and serum hepatitis C virus-RNA levels 100 KIU/mL at baseline. The end-point of PSE was a volume of splenic infarction over 75%. Peginterferon alpha-2b at a dose of 1.2 μg/kg was administered by subcutaneous injection once a week. The dose of ribavirin was weight adjusted. Results PSE was successfully performed without serious adverse events. The period from PSE to starting the combined therapy was 14 (6-27) days. After PSE, platelet counts were significantly increased. In PSE group, platelet counts during the combined therapy were maintained above those at baseline. In non-PSE group, platelet counts at the 2nd week after the start of the combined therapy significantly decreased to less than those at baseline. Overall, 80% adherence to expected peginterferon dose was not achieved in 5 patients (45%) of PSE group and in 11 (85%) of non-PSE group (p=0.043). Conclusion Increased platelet counts after PSE facilitates the adherence to peginterferon therapy in chronic hepatitis C patients with thrombocytopenia.

Original languageEnglish
Pages (from-to)2731-2736
Number of pages6
JournalInternal Medicine
Volume50
Issue number22
DOIs
Publication statusPublished - Nov 18 2011

Fingerprint

Chronic Hepatitis C
Thrombocytopenia
Platelet Count
Ribavirin
Therapeutics
Splenic Infarction
Subcutaneous Injections
Hepacivirus
RNA
Weights and Measures
Serum

Keywords

  • Chronic hepatitis c
  • Partial splenic embolization
  • Peginterferon
  • Thrombocytopenia

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Takahara, M., Miyake, Y., Miyatake, H., Imagawa, A., Nakatsu, M., Ando, M., ... Yamamoto, K. (2011). Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. Internal Medicine, 50(22), 2731-2736. https://doi.org/10.2169/internalmedicine.50.6143

Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. / Takahara, Masahiro; Miyake, Yasuhiro; Miyatake, Hirokazu; Imagawa, Atsushi; Nakatsu, Morihito; Ando, Masaharu; Hirohata, Mamoru; Yamamoto, Kazuhide.

In: Internal Medicine, Vol. 50, No. 22, 18.11.2011, p. 2731-2736.

Research output: Contribution to journalArticle

Takahara, M, Miyake, Y, Miyatake, H, Imagawa, A, Nakatsu, M, Ando, M, Hirohata, M & Yamamoto, K 2011, 'Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia', Internal Medicine, vol. 50, no. 22, pp. 2731-2736. https://doi.org/10.2169/internalmedicine.50.6143
Takahara, Masahiro ; Miyake, Yasuhiro ; Miyatake, Hirokazu ; Imagawa, Atsushi ; Nakatsu, Morihito ; Ando, Masaharu ; Hirohata, Mamoru ; Yamamoto, Kazuhide. / Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. In: Internal Medicine. 2011 ; Vol. 50, No. 22. pp. 2731-2736.
@article{67e31086c12e4dbbb3970806e882fcf6,
title = "Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia",
abstract = "Objective Platelet counts before starting the treatment affect the discontinuation and dose reduction of peginterferon in chronic hepatitis C. Thrombocytopenia leads to failure to achieve sustained virological response. This study was undertaken to evaluate the efficacy of partial splenic embolization (PSE) prior to starting peginterferon therapy combined with ribavirin in chronic hepatitis C patients showing thrombocytopenia.Patients and Methods We compared the clinical features of 11 patients receiving PSE (PSE group) prior to starting the combined therapy with those of 13 patients not receiving PSE (non-PSE group). All of the patients showed platelet counts 12×10 4/mm 3 and serum hepatitis C virus-RNA levels 100 KIU/mL at baseline. The end-point of PSE was a volume of splenic infarction over 75{\%}. Peginterferon alpha-2b at a dose of 1.2 μg/kg was administered by subcutaneous injection once a week. The dose of ribavirin was weight adjusted. Results PSE was successfully performed without serious adverse events. The period from PSE to starting the combined therapy was 14 (6-27) days. After PSE, platelet counts were significantly increased. In PSE group, platelet counts during the combined therapy were maintained above those at baseline. In non-PSE group, platelet counts at the 2nd week after the start of the combined therapy significantly decreased to less than those at baseline. Overall, 80{\%} adherence to expected peginterferon dose was not achieved in 5 patients (45{\%}) of PSE group and in 11 (85{\%}) of non-PSE group (p=0.043). Conclusion Increased platelet counts after PSE facilitates the adherence to peginterferon therapy in chronic hepatitis C patients with thrombocytopenia.",
keywords = "Chronic hepatitis c, Partial splenic embolization, Peginterferon, Thrombocytopenia",
author = "Masahiro Takahara and Yasuhiro Miyake and Hirokazu Miyatake and Atsushi Imagawa and Morihito Nakatsu and Masaharu Ando and Mamoru Hirohata and Kazuhide Yamamoto",
year = "2011",
month = "11",
day = "18",
doi = "10.2169/internalmedicine.50.6143",
language = "English",
volume = "50",
pages = "2731--2736",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "22",

}

TY - JOUR

T1 - Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia

AU - Takahara, Masahiro

AU - Miyake, Yasuhiro

AU - Miyatake, Hirokazu

AU - Imagawa, Atsushi

AU - Nakatsu, Morihito

AU - Ando, Masaharu

AU - Hirohata, Mamoru

AU - Yamamoto, Kazuhide

PY - 2011/11/18

Y1 - 2011/11/18

N2 - Objective Platelet counts before starting the treatment affect the discontinuation and dose reduction of peginterferon in chronic hepatitis C. Thrombocytopenia leads to failure to achieve sustained virological response. This study was undertaken to evaluate the efficacy of partial splenic embolization (PSE) prior to starting peginterferon therapy combined with ribavirin in chronic hepatitis C patients showing thrombocytopenia.Patients and Methods We compared the clinical features of 11 patients receiving PSE (PSE group) prior to starting the combined therapy with those of 13 patients not receiving PSE (non-PSE group). All of the patients showed platelet counts 12×10 4/mm 3 and serum hepatitis C virus-RNA levels 100 KIU/mL at baseline. The end-point of PSE was a volume of splenic infarction over 75%. Peginterferon alpha-2b at a dose of 1.2 μg/kg was administered by subcutaneous injection once a week. The dose of ribavirin was weight adjusted. Results PSE was successfully performed without serious adverse events. The period from PSE to starting the combined therapy was 14 (6-27) days. After PSE, platelet counts were significantly increased. In PSE group, platelet counts during the combined therapy were maintained above those at baseline. In non-PSE group, platelet counts at the 2nd week after the start of the combined therapy significantly decreased to less than those at baseline. Overall, 80% adherence to expected peginterferon dose was not achieved in 5 patients (45%) of PSE group and in 11 (85%) of non-PSE group (p=0.043). Conclusion Increased platelet counts after PSE facilitates the adherence to peginterferon therapy in chronic hepatitis C patients with thrombocytopenia.

AB - Objective Platelet counts before starting the treatment affect the discontinuation and dose reduction of peginterferon in chronic hepatitis C. Thrombocytopenia leads to failure to achieve sustained virological response. This study was undertaken to evaluate the efficacy of partial splenic embolization (PSE) prior to starting peginterferon therapy combined with ribavirin in chronic hepatitis C patients showing thrombocytopenia.Patients and Methods We compared the clinical features of 11 patients receiving PSE (PSE group) prior to starting the combined therapy with those of 13 patients not receiving PSE (non-PSE group). All of the patients showed platelet counts 12×10 4/mm 3 and serum hepatitis C virus-RNA levels 100 KIU/mL at baseline. The end-point of PSE was a volume of splenic infarction over 75%. Peginterferon alpha-2b at a dose of 1.2 μg/kg was administered by subcutaneous injection once a week. The dose of ribavirin was weight adjusted. Results PSE was successfully performed without serious adverse events. The period from PSE to starting the combined therapy was 14 (6-27) days. After PSE, platelet counts were significantly increased. In PSE group, platelet counts during the combined therapy were maintained above those at baseline. In non-PSE group, platelet counts at the 2nd week after the start of the combined therapy significantly decreased to less than those at baseline. Overall, 80% adherence to expected peginterferon dose was not achieved in 5 patients (45%) of PSE group and in 11 (85%) of non-PSE group (p=0.043). Conclusion Increased platelet counts after PSE facilitates the adherence to peginterferon therapy in chronic hepatitis C patients with thrombocytopenia.

KW - Chronic hepatitis c

KW - Partial splenic embolization

KW - Peginterferon

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=81155153690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155153690&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.50.6143

DO - 10.2169/internalmedicine.50.6143

M3 - Article

C2 - 22082883

AN - SCOPUS:81155153690

VL - 50

SP - 2731

EP - 2736

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 22

ER -